Genital Diseases, Female  >>  Arenegyr (NGR-hTNF)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Arenegyr (NGR-hTNF) / AGC Biologics
NCT00484432 / 2007-000004-33: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer

Completed
2
37
Europe
NGR-hTNF, doxorubicin
AGC Biologics S.p.A.
Ovarian Cancer Metastatic Recurrent
06/16
06/16
NCT01358071 / 2010-023613-61: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

Completed
2
119
Europe
NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin
AGC Biologics S.p.A.
Ovarian Cancer
12/16
12/16

Download Options